Skip to content

MammoScreen 2.0

by Therapixel

510(k) K211541

Active European Union and United States

CE MDD 510(k)

Valid until

No date given

CE: no date in EUDAMED. FDA: not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

None linked in EUDAMED

A group certificate may exist

Trust

Unverified

Source EUDAMED, FDA 510(k), synced 6 Oct 2026.

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE 510(k) Substantially Equivalent · Traditional NumberK211541 Date26 Nov 2021ClearedStatusActive
European UnionCE/MDD EUDAMED Number— Date—StatusActive

Official records

From the FDA record

Received by the FDA
19 May 2021
FDA decision
26 Nov 2021 (Substantially Equivalent)
FDA review time
191 days from receipt to decision
Public document
510(k) summary on file with the FDA

From the FDA 510(k) record K211541 (openFDA), as read on 6 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Across registries

2 registries list this device

  • FDA 510(k) K211541 decided 26 Nov 2021 Active
  • EUDAMED Active

Coverage

2 jurisdictions

United States of AmericaSwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered
  • European Union CE/MDD Active
  • United States FDA 510(k) Active

Specification

EUDAMED · 510(k)

510(k) Number
FDA product code
QDQ
Device class
Class II
Regulation
21 CFR Part 892.2090
Advisory committee
Radiology
FDA decision
SESE Substantially Equivalent

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

MammoScreen 2.0 is a Radiological Computer Assisted Detection/Diagnosis Software for Lesions Suspicious for Cancer, designed to assist radiologists in the analysis of mammographic images. It employs AI-based algorithms to detect and evaluate suspicious lesions in both 2D and 3D mammograms, enhancing diagnostic accuracy and workflow efficiency.

This software is supplied as a digital solution, intended for use in radiology departments within healthcare facilities. It operates as a standalone application, requiring no physical sterilisation or single-use considerations, and is compatible with standard MRI-safe environments. The device is authorised under FDA 510K and MDD, with a classification of Class II. Multiple registration numbers (e.g., 3023522713) correspond to its various software versions and configurations.

Devices cleared under K211541

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under K211541
UDI-DISize and differences
MammoScreen MAL2US
Therapixel
MAL2USB885MAML2US0 —On the market

Similar devices

Other devices filed under FDA product code QDQ (Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer).

Other devices from Therapixel

  • MammoScreen MAL2US

    Class II
  • MammoScreen MAML

    Class II
  • MammoScreen BD

    Class II
  • MammoScreen (3)

    Class II

See all devices from Therapixel →